A 17β-Estradiol–Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial

(Abstracted from Obstet Gynecol 2018;132:161–170) After the first publication of Women's Health Initiative findings in 2002, many women stopped taking US Food and Drug Administration (FDA)–approved, hormone therapy (HT) and started using non–FDA-approved, “natural” compounded HT believing that it was a safer option. In 2015, it was estimated that 1 million to 2.5 million US women used the unapproved, compounded HT.